Parkside Financial Bank & Trust Has $1.17 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

Parkside Financial Bank & Trust cut its stake in Merck & Co., Inc. (NYSE:MRKGet Rating) by 3.4% in the second quarter, Holdings Channel.com reports. The firm owned 12,844 shares of the company’s stock after selling 457 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Merck & Co., Inc. were worth $1,170,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MRK. Bromfield Sneider Wealth Advisors acquired a new position in shares of Merck & Co., Inc. during the 1st quarter worth about $79,000. Hikari Power Ltd raised its holdings in shares of Merck & Co., Inc. by 5.0% in the 1st quarter. Hikari Power Ltd now owns 23,630 shares of the company’s stock valued at $1,939,000 after purchasing an additional 1,130 shares during the period. Financial Management Professionals Inc. raised its holdings in shares of Merck & Co., Inc. by 9.3% in the 2nd quarter. Financial Management Professionals Inc. now owns 3,414 shares of the company’s stock valued at $311,000 after purchasing an additional 291 shares during the period. ACG Wealth raised its holdings in shares of Merck & Co., Inc. by 5.6% in the 1st quarter. ACG Wealth now owns 13,523 shares of the company’s stock valued at $1,110,000 after purchasing an additional 722 shares during the period. Finally, Mascoma Wealth Management LLC raised its holdings in shares of Merck & Co., Inc. by 36.4% in the 1st quarter. Mascoma Wealth Management LLC now owns 926 shares of the company’s stock valued at $76,000 after purchasing an additional 247 shares during the period. 73.33% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 1.7 %

Shares of MRK opened at $84.53 on Thursday. Merck & Co., Inc. has a 12 month low of $71.50 and a 12 month high of $95.72. The firm’s 50 day moving average is $88.96 and its 200-day moving average is $87.74. The stock has a market capitalization of $214.14 billion, a PE ratio of 12.94, a P/E/G ratio of 1.16 and a beta of 0.33. The company has a current ratio of 1.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.66.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.20. The business had revenue of $14.59 billion for the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The firm’s revenue for the quarter was up 28.0% on a year-over-year basis. During the same quarter last year, the business posted $1.31 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be given a dividend of $0.69 per share. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 annualized dividend and a dividend yield of 3.27%. Merck & Co., Inc.’s dividend payout ratio is 42.27%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Daiwa Capital Markets raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and upped their target price for the company from $89.00 to $102.00 in a report on Wednesday, July 6th. Erste Group Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Thursday, August 25th. Berenberg Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and upped their target price for the company from $95.00 to $100.00 in a report on Wednesday, September 14th. Mizuho began coverage on shares of Merck & Co., Inc. in a report on Friday, June 24th. They issued a “buy” rating and a $100.00 price target on the stock. Finally, Cowen increased their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a report on Monday, June 27th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $98.28.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.